Form 4: Adverum Biotechnologies CFO Linda Rubinstein Reports Acquisition of Shares and Stock Options
SEC Form 4
Linda Rubinstein, CFO of Adverum Biotechnologies, reports the acquisition of common stock and stock options, as well as holdings following reported transactions.
Summary
- Linda Rubinstein, the Chief Financial Officer of Adverum Biotechnologies, filed a Form 4 detailing changes in her beneficial ownership of the company's securities.
- On February 25, 2025, Rubinstein acquired 8,125 shares of common stock upon settlement of a restricted stock unit (RSU) grant.
- These RSUs vest in equal installments on each anniversary of March 1, 2025, over three years, contingent upon her continued service with the company.
- Rubinstein also acquired options to purchase 48,750 shares of common stock at an exercise price of $4.20.
- These options vest over four years, with 25% vesting one year after March 1, 2025, and the remainder vesting monthly thereafter, also contingent upon continued service.
- Following these transactions, Rubinstein directly owns 19,325 shares of Adverum Biotechnologies common stock and options to purchase 48,750 shares.
- The report also notes that Rubinstein purchased 600 shares on May 20, 2024 and 600 shares on November 20, 2024, pursuant to the Issuer's 2014 Employee Stock Plan Purchase Plan, as amended and restated.
- The report also notes that on March 21, 2024, the Common Stock of Issuer split 1-for-10, resulting in a proportionate reduction of Reporting Person's shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing reflecting compensation and insider trading activity, neither overtly positive nor negative.
Positives
- The acquisition of shares and options by the CFO could be interpreted as a sign of confidence in the company's future prospects.
- The vesting schedules for the RSUs and options incentivize continued service and alignment with long-term company performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.
Stakeholder Impact
- The filing provides transparency to shareholders regarding insider transactions.
- Employees may be impacted through the employee stock purchase plan.
Key Dates
| Date | Description |
|---|---|
| 2024-03-21 | Common Stock of Issuer split 1-for-10, resulting in a proportionate reduction of Reporting Person's shares. |
| 2024-05-20 | Rubinstein purchased 600 shares pursuant to the Issuer's 2014 Employee Stock Plan Purchase Plan, as amended and restated. |
| 2024-11-20 | Rubinstein purchased 600 shares pursuant to the Issuer's 2014 Employee Stock Plan Purchase Plan, as amended and restated. |
| 2025-02-25 | Date of transaction: acquisition of common stock and stock options. |
| 2025-02-27 | Date of signature for the Form 4 filing. |
| 2025-03-01 | Vesting Commencement Date for RSUs. |
| 2035-02-24 | Expiration date for stock options. |
Keywords
Adverum Biotechnologies, Linda Rubinstein, CFO, Form 4, Beneficial Ownership, Stock Options, RSU, Shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.